pharmaceutical industry

See the following -

Merchants Of Meth: How Big Pharma Keeps The Cooks In Business

Jonah Engle | Mother Jones | July 1, 2013

With big profits on the line, the drug industry is pulling out campaign-style dirty tricks to keep selling the meds that cooks turn into crank. Read More »

Merck 'Evergreens' Off-Patent Lipitor By Creating Combination Drug With No Additional Benefit

Glyn Moody | Techdirt | July 8, 2013

Big pharma often gets a rather rough ride here on Techdirt, what with its attempts to stop governments granting licenses for life-saving and low-cost generics in emerging countries, engaging in legal action to prevent drug safety information being released, and paying kickbacks to doctors. Read More »

New Drugs Trail Many Old Ones In Effectiveness Against Disease

Sharon Begley | Reuters | June 3, 2013

Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, drugmakers have barely improved on old standbys developed decades ago. Read More »

NIH Broadens Its Role In Data Science

Anthony Brino | Government Health IT | January 11, 2013

The National Institutes of Health (NIH) is putting a fresh emphasis on health informatics, with Director Francis Collins, MD, creating a new advisory position and recruiting an associate director for Data Science. Read More »

NIH Launches Database Of Liver Injury-Linked Drugs

Anthony Brino | Government Health IT | October 15, 2012

The National Institutes of Health (NIH) has launched a database of pharmaceutical drugs associated with liver damage. Read More »

NIH Showcases Informatics Researchers As New Open Source Ventures Launch

Anthony Brino | Government Health IT | November 9, 2012

After the National Institutes of Health grew interested in bioinformatics, following breakthroughts in the 1990s, the National Centers for Biomedical Computing were created with the goal of advancing the field by a few leaps and bounds, because IT systems hadn’t quite caught up to molecular biology. Read More »

On the Lack of Good Medical Evidence for the New $100,000 Hepatitis C Drug Treatments

As we wrote, most recently last week, the hepatitis C screening and treatment bandwagon keeps rolling along.  There is constant public argument whether about the prices of treatment regimens, which approach $100,000 per patient in the US...However, starting in March, 2014, we have posted about the lack of good evidence from clinical research suggesting these drugs are in fact so wondrous...

Read More »

Open PHACTS: Semantic Technologies And Drug Discovery

Claire Bower | BMJ Web Development Blog | April 26, 2013

Research and discovery in the life sciences is a pretty complicated business. The complexity of the modern scientific process seems to be a reflection of the intricacies of life and the processes associated with disease and its treatment. Furthermore, as technologies become more advanced, so too does the problem of managing the ever expanding quantity of data being generated. Read More »

Open Source Effort Develops Affordable Drugs

Press Release | Stevens Institute of Technology | March 14, 2013

In order to accelerate the development of new drugs to combat and cure major infectious diseases, Professor A.K. Ganguly of the Department of Chemistry, Chemical Biology & Biomedical Engineering at Stevens Institute of Technology is contributing his expertise and passion to the Council of Scientific and Industrial Research (CSIR) Open Source Drug Discovery initiative. Read More »

Open-Access Method Toolbox Software

Press Release | Shimadzu Scientific Instruments Inc. | March 20, 2013

Shimadzu Scientific Instruments Inc. has released the Method Toolbox, the newest addition to its Open Solutions family of open-access software. Method Toolbox is purification method scouting software that assists with method optimization to increase the productivity of pharmaceutical laboratories and contract research organizations. Read More »

Patients Matter Most, But Technology Matters A Lot

Andy Oram | O'Reilly Strata | June 1, 2013

Computing practices that used to be religated to experimental outposts are now taking up residence at the center of the health care field. From natural language processing to machine learning to predictive modeling, you see people promising at the health data forum (Health Datapalooza IV) to do it in production environments. Read More »

Pfizer Shares Software For Biotech Drug Research With Pharma Rivals

Ryan McBride | FierceBiotechIT | June 24, 2013

Pfizer ($PFE) has led the way in an effort to share software and standards for managing data on complex molecules, providing the tech know-how on a precompetitive basis to competitors such as GlaxoSmithKline ($GSK), Roche ($RHHBY) and Bristol-Myers Squibb ($BMY). Read More »

Pharma Not So Big On Cloud For Clinical Trials

Chris Anderson | Government Health IT | December 26, 2012

Big pharma is notoriously slow-footed when it comes to changing its business model. Some would argue it is a major reason why so many pharmaceutical companies are struggling as their blockbuster drugs go off patent. In short, there is an institutionalized caution to embracing the kind of change moving to the cloud presents.

Read More »

Pharmacists Told To Work In PHCs Too

Staff Writer | The New Indian Express | June 3, 2013

Urging qualified pharmacists to take greater roles in the healthcare sector, former president A P J Abdul Kalam on Sunday said they must be given a chance to serve at public health centres (PHCs) and community health centres (CHCs). Read More »

Phase II Trials Of TB Drug Through Open Source Drug Discovery Programme To Begin Soon

Joseph Alexander | Pharmabiz.com | July 22, 2013

The search for a new tuberculosis drug after many decades and first time through a unique model of open drug discovery programme may finally bear fruits in near future, with India all set for the launch of the phase II clinical trial of the drug candidate. Read More »